全文获取类型
收费全文 | 150251篇 |
免费 | 10951篇 |
国内免费 | 1004篇 |
专业分类
耳鼻咽喉 | 644篇 |
儿科学 | 2645篇 |
妇产科学 | 2273篇 |
基础医学 | 12434篇 |
口腔科学 | 7700篇 |
临床医学 | 20464篇 |
内科学 | 19347篇 |
皮肤病学 | 1940篇 |
神经病学 | 10031篇 |
特种医学 | 2425篇 |
外国民族医学 | 1篇 |
外科学 | 15456篇 |
综合类 | 11164篇 |
现状与发展 | 4篇 |
一般理论 | 96篇 |
预防医学 | 39680篇 |
眼科学 | 1488篇 |
药学 | 6924篇 |
92篇 | |
中国医学 | 3502篇 |
肿瘤学 | 3896篇 |
出版年
2024年 | 421篇 |
2023年 | 3218篇 |
2022年 | 4403篇 |
2021年 | 6714篇 |
2020年 | 6035篇 |
2019年 | 9646篇 |
2018年 | 9297篇 |
2017年 | 7219篇 |
2016年 | 4622篇 |
2015年 | 4516篇 |
2014年 | 7214篇 |
2013年 | 9206篇 |
2012年 | 6129篇 |
2011年 | 6844篇 |
2010年 | 5268篇 |
2009年 | 5147篇 |
2008年 | 5029篇 |
2007年 | 4998篇 |
2006年 | 4335篇 |
2005年 | 3378篇 |
2004年 | 2896篇 |
2003年 | 2597篇 |
2002年 | 1951篇 |
2001年 | 1925篇 |
2000年 | 1633篇 |
1999年 | 1227篇 |
1998年 | 949篇 |
1997年 | 787篇 |
1996年 | 655篇 |
1995年 | 518篇 |
1994年 | 453篇 |
1993年 | 447篇 |
1992年 | 380篇 |
1991年 | 331篇 |
1990年 | 255篇 |
1989年 | 228篇 |
1988年 | 241篇 |
1985年 | 2936篇 |
1984年 | 3448篇 |
1983年 | 2911篇 |
1982年 | 3369篇 |
1981年 | 3060篇 |
1980年 | 2559篇 |
1979年 | 2529篇 |
1978年 | 2097篇 |
1977年 | 1570篇 |
1976年 | 2026篇 |
1975年 | 1546篇 |
1974年 | 1343篇 |
1973年 | 1282篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
41.
42.
43.
44.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
45.
《Neuro-Chirurgie》2022,68(3):262-266
BackgroundThe prognosis for patients with recurrent glioblastoma (GBM) is dismal, and the question of repeat surgery at time of recurrence is common. Re-operation in the management of these patients remains controversial, as there is no randomized evidence of benefit. An all-inclusive pragmatic care trial is needed to evaluate the role of repeat resection.Methods3rGBM is a multicenter, pragmatic, prospective, parallel-group randomized care trial, with 1:1 allocation to repeat resection or standard care with no repeat resection. To test the hypothesis that repeat resection can improve overall survival by at least 3 months (from 6 to 9 months), 250 adult patients with prior resection of pathology-proven glioblastoma for whom the attending surgeon believes repeat resection may improve quality survival will be enrolled. A surrogate measure of quality of life, the number of days outside of hospital/nursing/palliative care facility, will also be compared. Centers are invited to participate without financial compensation and without contracts. Clinicians may apply to local authorities to approve an investigator-led in-house trial, using a common protocol, web-based randomization platform, and simple standardized case report forms.DiscussionThe 3rGBM trial is a modern transparent care research framework with no additional risks, tests, or visits other than what patients would encounter in normal care. The burden of proof remains on repeat surgical management of recurrent GBM, because this management has yet to be shown beneficial. The trial is designed to help patients and surgeons manage the uncertainty regarding optimal care.Clinical Trial Registrationhttp://www.clinicaltrials.gov. Unique identifier: NCT04838782. 相似文献
46.
47.
对微信平台在住院病人健康教育中的应用现状进行总结,分析其目前成果、平台构建现状与存在的问题,为医院护理人员进行健康宣教提供参考。 相似文献
48.
49.
沈曙铭 《中华口腔医学杂志》2020,(4):241-245
突发公共卫生事件应急管理是一个全球性的课题。本文就2019年12月以来发生在中国的新型冠状病毒肺炎这一突发公共卫生事件,口腔医疗机构及其从业人员面临的相关问题进行法律层面的分析与思考,以期对口腔医疗行业应对突发公共卫生事件提供帮助和指导。 相似文献